Beta Blockers: Classification, MOA, Pharmacology, and Propranolol in Detail

I. Classification of Beta Blockers

A. By Receptor Selectivity

Note: Cardioselectivity is relative, not absolute. At higher doses, β1-selective agents also block β2 receptors.

B. By Intrinsic Sympathomimetic Activity (ISA / Partial Agonist Activity)

• With ISA: Pindolol, Acebutolol, Carteolol, Penbutolol
  • These are partial agonists - they mildly activate β receptors while blocking full agonists. They cause less resting bradycardia and less adverse metabolic effects.
• Without ISA: Propranolol, Metoprolol, Atenolol, Timolol, Nadolol, Bisoprolol, Esmolol

C. By Lipid Solubility

D. By Duration

• Ultra-short acting: Esmolol (t½ ~9 min - used IV in acute settings)
• Short acting: Propranolol (t½ 3-6 hrs)
• Long acting: Atenolol, Nadolol, Bisoprolol (once daily)

E. Third-Generation Beta Blockers (with vasodilator activity)

• Carvedilol - non-selective β + α1 blockade
• Labetalol - non-selective β + α1 blockade (IV use in hypertensive emergencies)
• Nebivolol - β1-selective + nitric oxide-mediated vasodilation

II. Mechanism of Action of Beta Blockers

At β1 Receptors (heart, kidney, adipose):

• Heart: Decrease heart rate (negative chronotropy), contractility (negative inotropy), and conduction velocity through the AV node (negative dromotropy) → reduced cardiac output
• Kidney: Inhibit renin secretion by juxtaglomerular cells → reduced angiotensin II → reduced aldosterone → lower blood pressure
• Net effect: Reduced cardiac output + reduced renin-angiotensin-aldosterone system activation

At β2 Receptors (non-selective agents only):

• Bronchi: Bronchoconstriction (dangerous in asthmatics)
• Vascular smooth muscle: Some vasoconstriction
• Metabolic effects: Inhibition of glycogenolysis and glucagon secretion → may mask tachycardia of hypoglycemia; prolonged hypoglycemia in diabetics
• Uterus: Inhibit uterine relaxation

Additional mechanisms for some agents:

• Membrane-stabilizing activity (MSA/quinidine-like): Propranolol, acebutolol - inhibit fast sodium channels (relevant mainly at toxic doses)
• α1 blockade: Carvedilol, labetalol - peripheral vasodilation
• ISA: Pindolol - partial β agonism reduces resting bradycardia

III. Pharmacological Actions of Beta Blockers

Cardiovascular:

• Decreased heart rate and myocardial contractility → reduced myocardial oxygen demand
• Slowed AV nodal conduction → useful in tachyarrhythmias
• Reduced blood pressure (via decreased CO and renin inhibition)
• Reduced infarct size and mortality post-MI (cardioprotective via reduced O₂ demand and anti-arrhythmic effect)
• In heart failure: beneficial remodeling, reduced sudden death risk

Renal:

• Reduced renin release → mild natriuresis

Metabolic:

• Inhibit glycogenolysis → risk of hypoglycemia
• Impair tachycardia response that signals hypoglycemia (masking)
• Mild increase in serum triglycerides; decrease HDL (especially non-selective agents)

Ophthalmic:

• Reduce aqueous humor production → lower intraocular pressure

CNS (lipophilic agents):

• Reduce anxiety, tremor, migraine frequency

IV. Propranolol: Detailed Profile

A. Mechanism of Action

1. Decreased cardiac output - reduced heart rate and contractility
2. Inhibition of renin release from the kidney (β1-mediated) → suppression of the renin-angiotensin-aldosterone system
3. Possible reduction of sympathetic vasoconstrictor nerve activity via presynaptic β-receptor blockade
4. CNS effects - reduces central sympathetic outflow (lipophilic, crosses BBB)

B. Pharmacokinetics

C. Therapeutic Uses of Propranolol

1. Hypertension - mild to moderate HTN (monotherapy or combination); particularly useful to prevent reflex tachycardia caused by direct vasodilators in severe HTN
2. Ischemic Heart Disease / Angina Pectoris - reduces myocardial O₂ demand by slowing HR and reducing contractility
3. Post-Myocardial Infarction - reduces infarct size, acute mortality, and long-term mortality when used after MI
4. Cardiac Arrhythmias - effective in supraventricular and ventricular arrhythmias; slows ventricular response in atrial flutter/fibrillation by increasing AV nodal refractory period; reduces catecholamine-induced ventricular ectopics
5. Thyrotoxicosis / Thyroid Storm - controls sympathetic symptoms (tachycardia, tremor, anxiety) while awaiting definitive therapy
6. Pheochromocytoma - used after α-blockade is established to control tachycardia (never use alone - risks hypertensive crisis due to unopposed α stimulation)
7. Essential Tremor - reduces peripheral tremor via β2 blockade in skeletal muscle
8. Migraine Prophylaxis - reduces frequency and severity
9. Anxiety / Performance Anxiety - controls somatic symptoms (palpitations, tremor)
10. Hypertrophic Obstructive Cardiomyopathy (HOCM) - reduces outflow tract obstruction, especially during exercise
11. Portal Hypertension - reduces portal pressure; prophylaxis against variceal bleeding
12. Glaucoma (topical timolol preferred; propranolol used systemically)

D. Adverse Effects of Propranolol

Cardiovascular:

• Bradycardia - can be severe in patients with pre-existing bradycardia or sick sinus syndrome
• AV block / worsening heart block - slows conduction
• Acute decompensation of heart failure (especially in patients with low ejection fraction dependent on sympathetic support)
• Peripheral vasoconstriction - cold extremities, worsening of Raynaud phenomenon and peripheral arterial disease (due to β2 blockade → unopposed α effects)

Respiratory:

• Bronchoconstriction - due to β2 blockade; dangerous in asthma and COPD (this is the most serious respiratory concern)

Metabolic / Endocrine:

• Masking of hypoglycemia - blunts tachycardia warning sign; sweating is preserved (cholinergic, not adrenergic)
• Prolonged hypoglycemia - by inhibiting glycogenolysis
• Dyslipidemia - elevated triglycerides, reduced HDL

CNS (lipophilic - crosses BBB):

• Fatigue, lethargy, sleep disturbances, nightmares
• Depression
• Cognitive impairment, memory difficulties
• Sexual dysfunction (impotence)

Withdrawal Syndrome:

• Abrupt discontinuation after prolonged use causes a rebound syndrome: nervousness, tachycardia, rebound angina, hypertension, and potentially myocardial infarction. This is due to up-regulation/supersensitivity of β receptors.
• Always taper gradually when discontinuing.

E. Contraindications of Propranolol

Absolute:

Relative:

V. Key Comparison: Propranolol vs. Cardioselective Agents